Skip to content

Prospective real world study for Chinese patent medicine in the adjuvant treatment of patients with acute coronary syndrome

Prospective real world study for Chinese patent medicine in the adjuvant treatment of patients with acute coronary syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR1900002467
Enrollment
Unknown
Registered
2019-07-14
Start date
2019-09-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease angina pectoris

Interventions

Sponsors

Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Participate voluntarily, understand and sign the informed consent form; 2. Aged 35-75 years old male and female; 3. Patients with acute coronary syndrome in the inpatient department or outpatient department of cardiology, include Unstable angina pectoris and non-ST-segment elevation myocardial infarction, resting angina pectoris, worsening exertional angina pectoris, variant angina pectoris, meet the diagnosis standard of angina pectoris issued by ACC/AHA, and Association of Cardiovascular Diseases of Chinese Medical Association and Editorial Board of Chinese Journal of Cardiovascular Diseases and the dialectical criteria of traditional Chinese medicine.

Exclusion criteria

Exclusion criteria: 1. Combined with other cardiac diseases,neurosis,climacteric syndrome,hyperthyroidism,cervical spondylosis of spinal cord or vertebral artery type, gastroesophageal reflux disease or hiatal hernia and other diseases that may cause chest pain; 2. Patients with angina pectoris with serious and uncontrollable symptoms,suffering from acute myocardial infarction, heart failure,myocarditis, cardiomyopathy, severe heart valve disease, liver failure or renal failure,malignant tumor, severe metabolic diseases and other major diseases; 3. Pregnant women,breast-feeding women or women of childbearing age who have fertility requirements; 4. Psychiatric patients, or cognitive dysfunction; 5. Have participated in other clinical trials in the past three months; 6. Allergic constitution or known allergy to therapeutic drugs; 7. It is estimated that compliance is poor and regular visits cannot be made; 8. Patients with no current address or incomplete current address and no contact number; 9. Researchers believe that there are other situations that are not suitable for participating in the experiment.

Design outcomes

Primary

MeasureTime frame
Percutaneous Coronary Intervention;Rate of acute Myocardial Infarction; Coronary Artery Bypass Grafting;

Secondary

MeasureTime frame
1. Carotid Artery Color Doppler Ultrasound, Cardiac Color Doppler Ultrasound, Electrocardiogram, Transcranial Color Doppler Ultrasound, Chest Radiograph and Other Imaging Examinations; 2. Clinical Biochemical Tests such as Troponin, Brain Natriuretic Peptide, Emergency Seven Items, Myocardial Enzyme, D- dimer, Coagulation Four Items;Death From All Causes;Degree of Angina Pectoris Pain, Frequency and Duration of Acute Angina Pectoris,etc;Readmission Due To Cardiovascular Events;

Countries

China

Contacts

Public ContactChunquan Yu

Tianjin University of Traditional Chinese Medicine

ycq-4@163.com+86 18622569428

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026